BEDFORD, Mass., April 15, 2025 /PRNewswire/ — Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolization, has announced the appointment of Daniel Davis to its Board of Directors.
Mr. Davis is Chief Strategy Officer at Imperative Care, where he has led growth, development, and strategic initiatives for its stroke and vascular technologies. Daniel has over 25 years of experience in sales, marketing, and business development with early-stage and Fortune 500 medical device companies. Before joining Imperative Care in 2020, Mr. Davis served as Chief Commercial Officer and President of North America at Penumbra, Inc., where he led the commercialization of embolization and mechanical thrombectomy technologies for neurovascular and peripheral vascular applications.
“We are very pleased to welcome Daniel Davis to the Board at Instylla. Daniel’s incisive leadership and deep industry experience will be a strong match for our Board as we drive commercialization for our next generation liquid embolics,” said Amar Sawhney, Chairman and CEO of Instylla, Inc. and Managing Director of Incept, LLC.
“I look forward to joining the Instylla Board of Directors at such a pivotal time, as the company advances the Embrace™ Hydrogel Embolic System toward commercialization, and brings the Tembo™ Embolic System to market,” said Mr. Davis. “Instylla has brought forward innovations that have the potential to transform treatment and outcomes, and I am honored to join Amar and the leadership team at this exciting time in the company’s growth.”
About Instylla:
Instylla, Inc. is a privately held company based in Bedford, MA, focused on developing novel resorbable embolic agents to advance interventional radiology, with initial clinical applications in interventional oncology and the peripheral vasculature. Instylla was founded in 2017 by Incept LLC and is funded by several leading venture capital groups.
To learn more, please visit https://www.instylla.com/
Caution: Embrace HES is an investigational device. Limited by Federal (or US) law to investigational use only. Not available for sale.
SOURCE Instylla, Inc.
NEW YORK--(BUSINESS WIRE)--Vent Creativity, a medical technology company advancing AI-enabled surgical planning, today announced the…
AEON Clinic Elevates Dubai to Global Hub for Longevity Science, A Definitive Four-Day Summit Defining…
Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…
Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…
Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…
Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment Primeadine Longevity Shot Primeadine…